bims-cytox1 Biomed news
on Cytochrome oxidase subunit 1
Issue of 2018‒09‒09
one paper selected by
Gavin McStay
Staffordshire University


  1. Adv Ther. 2018 Sep 01.
    Theodorou-Kanakari A, Karampitianis S, Karageorgou V, Kampourelli E, Kapasakis E, Theodossiadis P, Chatziralli I.
      INTRODUCTION: The purpose of this review is to present the current and emerging treatment alternatives for Leber's hereditary optic neuropathy (LHON), emphasizing the most recent use of idebenone and stem cells or gene therapy.METHODS: A comprehensive literature review was performed at the PubMed database regarding the various treatment modalities for LHON.
    RESULTS: Treatment modalities for LHON include nutritional supplements, activators of mitochondrial biogenesis, brimonidine, and symptomatic and supportive treatment, but nowadays attention is being paid to idebenone and gene therapy or stem cells.
    CONCLUSION: The treatment of LHON remains challenging, given the nature of the disease and its prognosis.
    Keywords:  Gene; Idebenone; Leber’s hereditary optic neuropathy; Nutritional supplements; Ophthalmology; Treatment
    DOI:  https://doi.org/10.1007/s12325-018-0776-z